Showing 8001-8010 of 10794 results for "".
- Galderma Sponsors 21st Annual SCOPE Miami Beach 2022 Art Showhttps://practicaldermatology.com/news/galderma-sponsors-21st-annual-scope-miami-beach-2022-art-show/2461447/Galderma is the exclusive aesthetic injectables sponsor of the 21st annual SCOPE Miami Beach 2022 art show. Galderma will be highlighting its aesthetics portfolio – Restylane, Dysport (abobotulinumtoxinA) and Sculptra – and hosting a variety of
- DefenAge Scores Defensin Master Anti-Aging Patenthttps://practicaldermatology.com/news/defenage-scores-defensin-master-anti-aging-patent/2461443/DefenAge Skincare received Defensin Master Anti-Aging Patent from the US Patent Office (Patent #11,491,096).
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- Case Study: Ulcer at Corner of Mouth May Be First Sign of Monkeypox Virushttps://practicaldermatology.com/news/case-study-ulcer-at-corner-of-mouth-may-be-first-sign-of-monkeypox-virus/2461429/Recent infection with monkeypox virus may initially present with an ulcer at the corner of the mouth, according to a case study of a 51-year-old HIV-positive patient published in Deutsches Ärzteblatt international</
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <
- High Rates of Skin Conditions Seen Among Urban-living Indigenous Kids in High-Income Countrieshttps://practicaldermatology.com/news/high-rates-of-skin-conditions-seen-among-urban-living-indigenous-kids-in-high-income-countries/2461421/Many urban-living Indigenous children and young people in high-income countries are burdened with atopic dermatitis and bacterial skin infections, according to Aasystematic analysis in Pediatric Dermatology. Invest
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis 
- New Aveeno Report Reveals 71% of Adults Have Sensitive Skinhttps://practicaldermatology.com/news/new-aveeno-report-reveals-71-of-adults-have-sensitive-skin/2461401/The Aveeno brand has launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The